All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2018-12-04T06:41:40.000Z

Bruno Paiva | ASH 2018 | The clinical significance of MRD for high-risk multiple myeloma 

By Vassiliki Fotaki
Featured
Bruno Paiva
Dec 4, 2018
Share:

Bookmark this article

60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA

Bruno Paiva
University of Navarra, Pamplona, ES

Bruno Paiva | ASH 2018 | The clinical significance of MRD for high-risk multiple myeloma 

More about...
ASHASH 2018High-riskRisk scores and prognostic tools

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
70 votes - 41 days left ...

Related articles

Add bookmark

Should risk-adapted MM treatment be informed by age or frailty status?

The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status?

Sep 12, 2023
Add bookmark

Should risk-adapted MM treatment be informed by age or frailty status?

The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM...

Sep 12, 2023
Add bookmark

How can MRD assessment help when treating patients with high-risk MM after transplantation?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Elena...

Apr 11, 2022
Add bookmark

How can MRD assessment help when treating patients with high-risk MM after transplantation?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the...

Apr 11, 2022
Add bookmark

Incorporating PET imaging in a new risk stratification system for NDMM

Patients with newly diagnosed multiple myeloma (NDMM) are risk stratified according to the Revised International Staging System (R-ISS) designed by the International Myeloma...

Feb 17, 2022
Add bookmark

Incorporating PET imaging in a new risk stratification system for NDMM

Patients with newly diagnosed multiple myeloma (NDMM) are risk stratified according to the Revised International Staging System...

Feb 17, 2022
Add bookmark

The Revised International Staging System (R-ISS) is a powerful tool for risk stratification of newly diagnosed MM patients 

The R-ISS is a powerful tool to identify groups of patients with distinct outcomes.

Mar 17, 2017
Add bookmark

The Revised International Staging System (R-ISS) is a powerful tool for risk stratification of newly diagnosed MM patients 

The R-ISS is a powerful tool to identify groups of patients with distinct...

Mar 17, 2017

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox